We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

140 hedge funds and large institutions have $974M invested in Crinetics Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 56 increasing their positions, 33 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

70% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 33

10% more capital invested

Capital invested by funds: $884M → $974M (+$89.8M)

9% more funds holding

Funds holding: 128 → 140 (+12)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

2.09% less ownership

Funds ownership: 102.14% → 100.05% (-2.1%)

93% less call options, than puts

Call options by funds: $32K | Put options by funds: $446K

Holders
140
Holders Change
+12
Holders Change %
+9.38%
% of All Funds
2.2%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
27
Increased
56
Reduced
33
Closed
15
Calls
$32K
Puts
$446K
Net Calls
-$414K
Net Calls Change
-$884K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$27.7M
2
BlackRock
BlackRock
New York
+$12.8M
3
IC
Ikarian Capital
Texas
+$9.47M
4
Jennison Associates
Jennison Associates
New York
+$9.2M
5
PBA
Paradigm Biocapital Advisors
New York
+$5.21M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$44M
2
PA
Perceptive Advisors
New York
-$32.1M
3
B
Braidwell
Connecticut
-$27.3M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.64M
5
Walleye Capital
Walleye Capital
New York
-$2.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
51
Barclays
United Kingdom
$1.66M -$343K -17,180 -16%
Two Sigma Investments
52
Two Sigma Investments
New York
$1.65M +$1.18M +59,335 +184%
RhumbLine Advisers
53
RhumbLine Advisers
Massachusetts
$1.62M +$165K +8,250 +10%
Swiss National Bank
54
Swiss National Bank
Switzerland
$1.48M +$17.9K +900 +1%
TCM
55
Tekla Capital Management
Massachusetts
$1.42M – – –
Prudential Financial
56
Prudential Financial
New Jersey
$1.29M +$1.43M +71,765 New
D.E. Shaw & Co
57
D.E. Shaw & Co
New York
$1.27M +$1.41M +70,590 New
Fisher Asset Management
58
Fisher Asset Management
Washington
$1.23M – – –
Two Sigma Advisers
59
Two Sigma Advisers
New York
$1.12M +$41.9K +2,100 +3%
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$1.07M +$7.42K +372 +0.6%
TD Asset Management
61
TD Asset Management
Ontario, Canada
$1.06M +$624K +31,300 +113%
UOC
62
UBS O'Connor
Illinois
$1.01M +$453K +22,732 +68%
Qube Research & Technologies (QRT)
63
Qube Research & Technologies (QRT)
United Kingdom
$1.01M +$893K +44,763 +406%
Citigroup
64
Citigroup
New York
$998K -$966K -48,433 -47%
AllianceBernstein
65
AllianceBernstein
Tennessee
$923K – – –
Manulife (Manufacturers Life Insurance)
66
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$922K +$613K +30,745 +151%
California State Teachers Retirement System (CalSTRS)
67
California State Teachers Retirement System (CalSTRS)
California
$918K -$34.3K -1,720 -3%
MAM
68
Martingale Asset Management
Massachusetts
$868K – – –
CSS
69
Cubist Systematic Strategies
Connecticut
$850K +$919K +46,092 +4,190%
AA
70
AlphaCentric Advisors
Puerto Rico
$847K +$937K +47,000 New
BC
71
BIT Capital
Germany
$817K +$106K +5,297 +13%
Wells Fargo
72
Wells Fargo
California
$795K +$262K +13,151 +42%
JP Morgan Chase
73
JP Morgan Chase
New York
$787K +$63K +3,161 +8%
CS
74
Credit Suisse
Switzerland
$771K +$221K +11,076 +35%
Millennium Management
75
Millennium Management
New York
$766K -$1.04M -52,279 -55%
1 2
3
4 5

CRNX Hedge Fund Activity: Q2 2023 in Review

140 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2023, worth a combined $974M — up 10% from $884M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CRNX positions and 15 closed out — a net gain of 12 holders — while 56 added to existing stakes and 33 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $27.7M. The largest seller was BVF Inc, exiting entirely with an estimated $44M sold.

  • 140 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2023, up from 128 in Q1 2023.
  • Funds reported $974M of Crinetics Pharmaceuticals stock for Q2 2023, up 10% quarter-over-quarter.
  • 27 funds opened new Crinetics Pharmaceuticals positions in Q2 2023 and 15 closed out, a net change of +12 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q2 2023 was T. Rowe Price Associates, an estimated $27.7M added.
  • The largest Crinetics Pharmaceuticals seller in Q2 2023 was BVF Inc, an estimated $44M sold.

Based on aggregated 13F filings for Q2 2023.